<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03168659</url>
  </required_header>
  <id_info>
    <org_study_id>25-3944</org_study_id>
    <nct_id>NCT03168659</nct_id>
  </id_info>
  <brief_title>CardioFocus HeartLight Post-Approval Study</brief_title>
  <official_title>Post-Approval Study of the HeartLight Endoscopic Ablation System for the Treatment of Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CardioFocus</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CardioFocus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a post-approval study to evaluate the clinical outcomes in a cohort of participants
      treated during commercial use of the HeartLight System to confirm results of the previously
      conducted pivotal clinical study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, open-label, multi-center, single arm study designed to assess
      continued safety and effectiveness of the HeartLight System during commercial use in
      participants being treated for drug refractory, symptomatic, paroxysmal atrial fibrillation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 16, 2017</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of participants free from symptomatic atrial fibrillation (AF) or symptomatic atypical atrial flutter/atrial tachycardia (AFL/AT) lasting longer than 30 seconds post the 90 day blanking period</measure>
    <time_frame>Day 91 through 12 months</time_frame>
    <description>The outcome will be assessed from 91 days post procedure through 12 months</description>
  </primary_outcome>
  <other_outcome>
    <measure>Chronic Effectiveness</measure>
    <time_frame>36 months</time_frame>
    <description>Freedom from symptomatic AF or symptomatic atypical AFL/AT</description>
  </other_outcome>
  <other_outcome>
    <measure>Chronic Safety</measure>
    <time_frame>36 months</time_frame>
    <description>Reporting of adverse events</description>
  </other_outcome>
  <other_outcome>
    <measure>Effect of Operator Experience on primary effectiveness endpoint</measure>
    <time_frame>36 months</time_frame>
    <description>Assess relationship between operator experience and freedom from symptomatic AF or symptomatic atypical AFL/AT</description>
  </other_outcome>
  <other_outcome>
    <measure>Effect of Operator Experience on primary safety endpoint</measure>
    <time_frame>36 months</time_frame>
    <description>Assess relationship between operator experience and rate of Primary Adverse Events (PAE)</description>
  </other_outcome>
  <other_outcome>
    <measure>Safety Outcomes by Gender</measure>
    <time_frame>12 months and 36 months</time_frame>
    <description>Assess relationship between gender and rate of PAEs</description>
  </other_outcome>
  <other_outcome>
    <measure>Neurological Events</measure>
    <time_frame>36 months</time_frame>
    <description>Assess relationship between neurological events and procedural parameters</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Pulmonary vein isolation ablation with HeartLight Endoscopic Ablation System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HeartLight</intervention_name>
    <description>HeartLight Endoscopic Ablation System</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ablation</intervention_name>
    <description>Pulmonary vein isolation ablation</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years or older

          -  planned for catheter ablation due to symptomatic paroxysmal atrial fibrillation

          -  failure of at least one anti-arrhythmic drug

          -  others

        Exclusion Criteria:

          -  overall good health as established by multiple criteria
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Study Director</last_name>
    <phone>508-658-7253</phone>
    <email>lhausmann@cardiofocus.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Arizona Sarver HeartCenter</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mathew Hutchinson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Illinois</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Erik Wissner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Betsy Ellsworth, MSN, ANP</last_name>
      <email>betsy.ellsworth@mountsinai.org</email>
    </contact>
    <investigator>
      <last_name>Srini Dukkipati, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Of Virginia Health System</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Jane Strickland</last_name>
      <phone>434-982-6401</phone>
      <email>MJS7W@hscmail.mcc.virginia.edu</email>
    </contact>
    <investigator>
      <last_name>J. Michael Mangrum, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 24, 2017</study_first_submitted>
  <study_first_submitted_qc>May 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 30, 2017</study_first_posted>
  <last_update_submitted>January 4, 2018</last_update_submitted>
  <last_update_submitted_qc>January 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

